Axiom MRC has updated all it's market research reports with the Economic Impact Analysis of COVID19 Pandemic on the market. Our team of analyst are following Comprehensive Three Dimensional (3D) Research Methodology along with large number primary interviews with key industry participants to bring insightful market reports to meet the current market requirements.
Liraglutide is an antidiabetic manufactured by Novo Nordisk. It is a member of a new class of anti-diabetic medications called GLP-1 analogs. These mirror the effects of naturally produced glucagon-like peptide-1 (GLP-1), which involves glucose-dependent stimulation of insulin secretion, suppression of glucagon secretion, reduction of appetite, and delay of food absorption. Liraglutide (NN2211) may be a long-acting glucagon-like peptide-1 receptor agonist, binding to equivalent receptors as does the endogenous metabolic hormone GLP-1 that stimulates insulin secretion. Marketed under the name Victoza, it’s an injectable drug developed by Novo Nordisk for the treatment of type 2 diabetes. Novo Nordisk began marketing it in the U.S. under the name Saxenda as a treatment for obesity in adults with a minimum of one weight-related comorbid condition.
The drug has been approved as an auxiliary treatment to diet and exercise to enhance glycaemic control in adults suffering from type 2 diabetes. The approval enables the drug to be used as a monotherapy, as a second-line treatment and also in combination with other oral medications prescribed for diabetes and thus is attributed to driving the market. However, taking under consideration the shortage of clinical test evidence showing a big enjoy increasing the liraglutide dose from 1.2 mg to 1.8 mg, the widely varying ICERs and the uncertainty in the economic analysis, the Committee was unable to recommend liraglutide 1.8 mg for the treatment of type 2 diabetes which is hampering the market growth.
The exclusive COVID 19 impact analysis report by Axiom MRC provides a 3600 analysis of micro and macro-economic factors on the pet grooming market. In addition, complete analysis of changes on the Pet grooming market expenditure, economic and international policies on supply and demand side. The report also studies the impact of pandemic on global economies, international trade, business investments, GDP and marketing strategies of key players present in the market. Liraglutide have their major role to treat the type 2 diabetes. Due COVID-19 the liranglutides market had a high demand due to inceasing inactivity owing to covid 19 situation. However, disruption of supply chain and production were affected due to COVID-19.
The Liraglutide market is segmented based on by type, by application and geography.
The Liraglutide market on the basis of type is segmented into Pills and Liquid. Liraglutide is mostly preferred in pills form and is thus attributed to hold the largest market share.
The Liraglutide market on the basis of Application is segmented into Hospital and Drug Store. Both hospitals and drug stores are attributed to drive the market shares equally.
Geographically the global Liraglutide market is studied for the following region North America, Europe, Asia Pacific, Middle East & Africa and Rest of the World. The largest share in the market will be dominated by Asia Pacific.
The major players in Liraglutide market are Bachem, HEC Pharm, Kingpep Biotechnology, Shenzhen JYMed Technology, Bharat Pharmaceuticals, Wuxi Asiapeptide, and AmbioPharm among others.
The report analyses the global Liraglutide market based on by type, by appplication and geography. The Liraglutide are available in market according to different types Pills and Liquid. Liraglutide is majorly applied in Hospital and Drug Store. Geographically the global Liraglutide market is studied for the following region North America, Europe, Asia Pacific, Middle East & Africa and RoW.
The major players in Liraglutide market are Bachem, HEC Pharm, Kingpep Biotechnology, Shenzhen JYMed Technology, Bharat Pharmaceuticals, Wuxi Asiapeptide, and AmbioPharm among others.
Why to buy this report:
